Lilly reports 79% response rate for Sofe-M in platinum-sensitive ovarian cancer
The Phase 1 study of sofetabart mipitecan (Sofe-M) plus bevacizumab in 29 patients with measurable disease reported a confirmed objective response rate of 79.3% (23/29) and a disease control rate of 100%. The most common grade ≥3 adverse events were neutropenia (42%) and anemia (24%), with 6% of patients discontinuing treatment due to an adverse event.
Primary source
Company press release (PR Newswire), October 24, 2026
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
Machine-summarized from the source above; not independently reported. How we use automation